Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Researchers describe findings in cancer vaccines studies
June 30th, 2005
Cancer vaccines research advances have been reported from Germany, the United States and the The Netherlands. Study 1: A single-chain Ep-CAM-/CD3-bispecific antibody construct eradicated tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice. "Bispecific T-cell engager (BiTE) are a class of bispecific single-chain antibodies that can very effectively redirect cytotoxic T cells for killing of tumor target cells. Here, we have assessed the in vivo efficacy of one representative, called bscEp-CAMxCD3, with specificity for tumors overexpressing epithelial cell adhesion molecule (Ep-CAM) in human xenograft...
Source: Women's Health Weekly (2005-06-30)
|
